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DNA methylation at the 5 position of cytosine (5-mC)
is a key epigenetic mark that is critical for various bio-
logical andpathological processes. 5-mC can be con-
verted to 5-hydroxymethylcytosine (5-hmC) by the
ten-eleven translocation (TET) family of DNA hydroxy-
lases. Here, we report that ‘‘loss of 5-hmC’’ is an epi-
genetic hallmark of melanoma, with diagnostic and
prognostic implications. Genome-wide mapping of
5-hmC reveals loss of the 5-hmC landscape in the
melanoma epigenome. We show that downregulation
of isocitrate dehydrogenase 2 (IDH2) and TET family
enzymes is likely one of the mechanisms underlying
5-hmC loss in melanoma. Rebuilding the 5-hmC land-
scape inmelanoma cells by reintroducing active TET2
or IDH2 suppresses melanoma growth and increases
tumor-free survival in animal models. Thus, our study
reveals a critical function of 5-hmC in melanoma
development and directly links the IDH and TET acti-
vity-dependent epigenetic pathway to 5-hmC-medi-
ated suppression ofmelanomaprogression, suggest-
ing a new strategy for epigenetic cancer therapy.
INTRODUCTION
Melanoma is a unique and highly aggressive type of cancer
that occurs more frequently with increasing age and often withCa significant contribution of environmental factors to its etiology
(Jemal et al., 2001, 2006; Marks, 2000). As one of the most
virulent human cancers, melanoma is capable of distant and
lethal metastases when the primary tumor volume is as little as
1 mm3. Studies of biomarkers predictive of clinical outcome
are impeded by latent periods for detection of metastases
that may range from several years to more than a decade, and
thus clinically annotated bio-specimen archives serve as
valuable surrogates for the otherwise impractical prospective
approaches. Such studies are further compounded by the
difficulties inherent in the diagnosis of melanoma, as certain
benign nevi and melanomas show significant histological over-
lap. Presently, there is a dearth of molecular markers that facili-
tate detecting the differences between benign and malignant
melanocytic lesions and assist in predicting their biological
behaviors. Thus, there is a pressing need for novel biomarkers
that define the malignant potential of primary lesions, predict
clinical outcome, and forecast therapeutic responses.
Abnormal DNAmethylation at the 5 position of cytosine (5-mC)
is a well-known epigenetic feature of cancer. Melanoma exhibits
global hypomethylation within the bulk genome and local hyper-
methylation at specific tumor suppressor genes (Hoon et al.,
2004; Liu et al., 2008; Shen et al., 2007). Nonetheless, the degree
of global hypomethylation in melanoma is not sufficient to
distinguish benign nevus from melanoma (Paz et al., 2003).
Gene-specific hypermethylation may be a better discriminator,
as recent studies indicate that multilocus DNA methylation sig-
nature genes may differentiate melanomas from nevi (Conway
et al., 2011; Tellez et al., 2009). However, this requires sophisti-
cated molecular biological tools that are not easily applicableell 150, 1135–1146, September 14, 2012 ª2012 Elsevier Inc. 1135
in routine clinical practice, and the small biopsy size of melano-
cytic lesions presents another technical limitation. Thus, despite
the increasing recognition that abnormal DNA methylation (and/
or histone modification) is a crucial participant in melanoma
progression, no characteristic epigenetic modifications have
been discovered that can be readily used as molecular markers
for diagnosis and evaluation of melanoma virulence.
The recent discovery of the ten-eleven translocation (TET)
family of 5-mC hydroxylases, including TET1, 2, and 3, which
convert 5-mC to 5-hydroxymethylcytosine (5-hmC), also known
as the ‘‘sixth base,’’ has added an additional layer of complexity
to the epigenetic regulation of DNA methylation (Ito et al., 2010;
Tahiliani et al., 2009; Zhang et al., 2010). 5-hmC exists at a high
level in self-renewing and pluripotent stem cells (Szwagierczak
et al., 2010; Tahiliani et al., 2009). However, 5-hmC levels are
greatly reduced in most cultured, immortalized tumor cells (Haff-
ner et al., 2011; Song et al., 2011; Yang et al., 2012). Frequent
TET2 mutational inactivation has been reported to associate
with decreased 5-hmC levels in various myeloid leukemias (Del-
hommeau et al., 2009; Langemeijer et al., 2009). In addition, the
cofactor a-ketoglutarate (a-KG) is absolutely required and plays
a positive and critical role in the conversion of 5-mC to 5-hmC
(Xu et al., 2011a). Isocitrate dehydrogenases (IDHs) catalyze
oxidative decarboxylation of isocitrate, producing a-KG and
CO2 (Reitman et al., 2011; Xu et al., 2011a). There are two major
IDH enzymes in mammalian cells—IDH1 in cytoplasm and its
homolog, IDH2, in mitochondria—which catalyze the same reac-
tion. It has been reported that gain-of-function mutations in IDH1
and IDH2 in cancer cells produce the oncometabolite 2-hydroxy-
glutarate (2-HG), an antagonist of a-KG (Chowdhury et al., 2011;
Xu et al., 2011a), which inhibits the TET-mediated conversion of
5-mC to 5-hmC. Moreover, similar to the frequent mutation rate
of IDH1 or IDH2 in glioma and myeloid leukemia (Dang et al.,
2010; Krell et al., 2011), 10%ofmelanomas harbor a neomorphic
mutation in IDH1 or IDH2 (Shibata et al., 2011). These studies
suggest a role of 5-hmC, TET, and IDH in malignancy. However,
it remains elusive as to how 5-hmC is lost andwhat roles TET and
IDH proteins play during tumor progression. In particular, it
remains unknown as to how this epigenetic mark and these
related enzymes partake in melanoma progression.
Using melanoma as a paradigm of aggressive cancer, here we
report that ‘‘loss-of-5-hmC’’ is a new epigenetic hallmark of
melanoma. We functionally characterize the significant impact
of 5-hmC, IDH2, and TET2 in melanoma progression. Impor-
tantly, we show that the activity of IDH2 and TET2 enzymes
required for the production of 5-hmC and the re-establishment
of the 5-hmC landscape in melanoma cells is essential to regula-
tion of melanoma virulence, contributing to our current under-
standing of cancer epigenetics.
RESULTS
5-hmCLevel IsHigh inMatureMelanocytes andNevi and
Is Lost in Human Melanomas
High levels of 5-hmC were detected by immunofluorescent (IF)
staining in the nuclei of isolated melanocytes that coexpressed
MART-1, a melanocyte-specific marker, within the epidermal
basal cell layer (Figures 1A and 1B). A more sensitive method1136 Cell 150, 1135–1146, September 14, 2012 ª2012 Elsevier Inc.for IF or immunohistochemical (IHC) staining of 5-hmC using
HCl-treated formalin-fixed, paraffin-embedded tissue sections
resulted in loss of theMART-1 epitope but significantly improved
the detection of 5-hmC as demonstrated by staining in normal
human tissues (Figure S1A available online). By this method,
strong IF staining of 5-hmC was detected in melanocytes within
the otherwise negative basal layer, as seen in Figures 1A and 1B,
as well as variably within more differentiated suprabasal kerati-
nocytes (Figure 1C). The IF staining pattern was confirmed by
IHC staining (Figure 1D), and this more sensitive method for
5-hmC detection was utilized for all subsequent studies of
melanocytic nevi and melanomas.
More than 50 individual cases of representative melanocytic
lesions, including benign nevi, primary melanomas, and meta-
static melanomas, were initially evaluated. Benign nevus cases
(n = 30) showed strong nuclear 5-hmC staining, whereas virtually
all tumor cells in primary (n = 15) and metastatic (n = 10) mela-
nomas showed partial or complete loss of 5-hmC (Figures 1E–
1H). Significant differences in other epimarks were not observed
between benign nevi andmelanomas (Figure S1B and Table S1),
suggesting the unique discriminatory nature of 5-hmC staining
as it relates to cells of melanocytic lineage. We next purified
genomic DNA from nevi and melanomas and confirmed higher
5-hmC levels in nevi than in melanomas by two independent
methods, the anti-5-hmC antibody-based dot blot (Figure 1I)
and T4 phage b-glucosyltransferase-mediated 5-hmC glucosy-
lation assay (Figure 1J). Taken together, these data demonstrate
that, while a high level of 5-hmC is a distinctive epigenetic
signature for melanocytes and benign nevi, significantly dimin-
ished or complete loss of 5-hmC is a feature of melanomas.
5-hmC Is a Putative Molecular Marker of Melanoma
Progression
We next examined 5-hmC levels by IHC using a melanoma
progression tissue microarray (TMA) representing four major
diagnostic tumor types: benign melanocytic nevus, primary
cutaneous melanoma, melanoma metastases to lymph nodes,
and metastases to viscera (Kabbarah et al., 2010; Schatton
et al., 2008). Consistent with the individual cases examined
above (Figure 1), the TMA confirmed significant 5-hmC loss in
primary melanomas and metastatic melanomas compared with
nevi (p < 0.001; Figures 2A and S2 and Tables S2 and S3). In
two additional commercially available melanoma TMAs, there
was significant loss of 5-hmC inmelanomas compared to benign
nevi (p = 1.1 3 107) and loss in nodal compared to visceral
metastases (p = 0.016) (Figure 2B). Taken together, these data
further support loss of 5-hmC as a distinctive epigenetic event
in melanoma and suggest that 5-hmC may represent a new
epigenetic mark for melanoma recognition and progression.
We next correlated the 5-hmC level with critical melanoma
staging parameters (tumor depth and mitotic rate) using the
melanoma specimens from a clinically annotated cohort
including 70 superficial spreading and nodular melanomas
(Table S4). There was a negative correlation between 5-hmC
staining score and primarymelanomaBreslow depth, a standard
predictor of prognosis (Figure 2C, r = 0.4, p = 0.0005), as well
as between 5-hmC level and mitotic rate (Figure 2D, r = 0.23,
p = 0.054). Furthermore, 5-hmC levels were significantly reduced
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Figure 1. 5-hmC Level Is High in Mature Melanocytes and Lost
in Melanomas
(A and B) IF costaining of 5-hmC and MART1 in normal human skin without
HCl treatment (4003). Green, 5-hmC; red, MART1; blue, DAPI counterstain of
DNA. Among basal-layer cells (dotted white line), 5-hmC-positive cells
exclusively proved to be MART-1-positive melanocytes (dotted circles).
(C and D) Detecting 5-hmC in normal human skin by IF (C) and IHC staining (D)
with HCl treatment (4003). Both methods showed strong nuclear staining in
isolated, solitary cells within the basal layer (dotted circles), in nuclei within the
uppermost epidermal layers.
(E–H) Representative histology of 5-hmC IHC staining in the individual cases
of benign and malignant melanocytic lesions. Low-power images (1003) on
the left column, with the dotted red areamagnified at high power (4003 ) on the
right column. All slides were counterstained with hematoxylin (light blue).
(I) Immunoblotting assay shows significantly higher 5-hmC levels in benign
nevi than in melanomas. Three representative immunoblot images are shown
here from the ten cases of each group.
Cin melanomas with Breslow values of > 1 mm compared to those
with Breslow values of% 1 mm (p < 0.01), and melanomas with
the presence of > 1 mitosis (a current predictor of nodal metas-
tasis) had less staining than those with % 1 mitosis (p < 0.05)
(Figure 2E and Tables S5 and S6). Similarly, 5-hmC levels in
pathological stage 1 melanomas were significantly higher than
in stage 2–3 melanomas (p < 0.05) and were significantly lower
in melanoma patients with ulceration (an important staging
parameter) than in those without ulceration (p < 0.05) (Figure 2E
and Tables S5 and S6). We further analyzed the association
between 5-hmC levels and the survival probability based on
data for all 70 patients (Table S4). Importantly, Kaplan-Meier
curves revealed that patients with 5-hmC-positive melanomas
(staining scoreR 1) had significantly higher survival probabilities
than patients with 5-hmC-negative melanomas (staining score =
0) at diagnosis (Figure 2F). Thus, loss of 5-hmC in melanoma
has both diagnostic and prognostic value in these biospecimen
cohorts.
Genome-wide Mapping of 5-hmC in Nevi
and Melanomas Reveals a Demolished 5-hmC
Landscape in the Epigenome of Melanomas
We next asked whether 5-hmC loss in melanoma is genome
wide or loci specific. We first investigated the 5-hmC level
changes at specific genomic loci by mapping the genome-
wide 5-hmC distribution in nevus and melanoma tissues using
a barcoded hydroxymethylated DNA immunoprecipitation
(hMeDIP) approach coupled with deep sequencing (hMeDIP-
seq) (Xu et al., 2011b) that permits quantitative comparisons of
genome-wide changes of 5-hmC between nevi and melanomas
(Figure S3A). Similar to our previous finding in mouse ES
cells (Xu et al., 2011b), we found that 5-hmC is associated
with gene-rich regions in the nevus genome (Figure 3A). Using
MACS software (Zhang et al., 2008), we identified a total
54,454 5-hmC peaks in nevi (p < 105, FDR < 0.01, fold enrich-
ment > 10) among which more than half are located either in
exons (13%) or introns (42.6%), and 13.9% are located at
promoters (Figures 3B and S3B). These 5-hmC peaks are asso-
ciated with 17,468 Refseq genes, in which 15,750 and 10,065
genes are modified by 5-hmC in gene bodies and promoters
(2k to +2k of transcriptional start sites [TSSs]), respectively.
There are 8,347 Refseq genes that are modified by 5-hmC
both at promoters and in gene bodies. However, we only identi-
fied 3,362 5-hmC peaks in melanomas using theMACS software
with the same cut-off values as for nevi (Figures 3B and S3B).
These peaks are only associated with 3,219 Refseq genes.
Importantly, we observed a significantly decreased 5-hmC level
within the averaged gene bodies and 20% of their up- and
downstream regions in melanomas in comparison to nevi
(Figure 3C). Indeed, we identified 41,886 out of 54,454 (77%)
total 5-hmC peaks in nevi whose normalized 5-hmC densities
were dramatically higher (>5-fold) than in melanomas. These(J) 5-hmC glucosylation assay confirms that the 5-hmC level in the genomic
DNA of nevi is significantly higher than that in melanomas. **p < 0.01 by
Student’s t test. Data are shown as mean ± SD (n = 3).
See also Figure S1 and Table S1.
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Figure 2. Loss of 5-hmC Correlated with
Melanoma Progression
(A) Analysis of 5-hmC levels in the SPORE TMA
represented by positive cell count score. Each
column represents a category of melanocytic
lesion (n = number of cases, each case has dupli-
cated tissue cores). Data are shown as mean ±
SEM. ***p < 0.001 compared to benign thin nevi;
#p < 0.001 compared to benign thick nevi.
(B) Combined cell count scores of 5-hmC staining
of three tissue microarrays. Each column repre-
sents a category of melanocytic lesion (n =
number of cases). Data are shown as mean ±
SEM. ***p < 0.001 compared to benign nevus,
#p < 0.05 compared to visceral metastases.
(C and D) The Spearman correlation between
Breslow depth and 5-hmC staining product
score (C) or between mitosis and 5-hmC staining
product score (D).
(E) 5-hmC staining product scores are correlated
with critical melanoma staging parameters. Data
are shown as mean ± SEM. *p < 0.05, **p < 0.01
by Student’s t test.
(F) Kaplan-Meier survival curves of melanoma
patients with positive 5-hmC staining (solid line)
and negative 5-hmC staining (dashed line). p <
0.05 by Gehan-Breslow-Wilcoxon Test.
See also Figure S2 and Tables S2–S6.41,886 peaks are located in 15,240 Refseq genes at either
promoters or gene bodies. Taken together, these analyses
indicate that loss of 5-hmC is a genome-wide event during
melanoma progression.
We next investigated whether the 5-mC genome-wide dis-
tribution is also altered in melanomas. We identified 33,374
and 28,830 5-mC peaks in nevi and melanomas (p < 105,
FDR < 0.01 and fold enrichment > 5), respectively (Figures 3B
and S3B). In contrast to 5-hmC, the genome-wide enrichment
and distribution pattern of 5-mC is similar between nevi and
melanomas, although a slight decrease of 5-mC in melanomas
was observed (Figures 3B and 3D), which is consistent with
the previously reported global DNA hypomethylation in mela-
nomas (Tellez et al., 2009).
To determine whether gene-specific changes of 5-hmC and
5-mC are associated with melanoma progression, we normal-
ized 5-hmC and 5-mC tag densities in nevus and melanoma
samples according to each input sequencing read, which
permitted quantitative comparison of 5-hmC and 5-mC signal
changes at specific genome loci. Because 5-hmC is converted
from 5-mC by TET enzymes, we reasoned that the decreased
5-hmC generation in melanomas would result in the accumula-
tion of its substrate, 5-mC, at certain genomic regions compared
to nevi. Indeed, we identified 2,144 peaks at which 5-hmC is
dramatically higher (>5-fold) and 5-mC is significantly lower1138 Cell 150, 1135–1146, September 14, 2012 ª2012 Elsevier Inc.(>2-fold) in 3,401 Refseq gene bodies in
nevi compared to melanomas (Figure 3E).
Importantly, KEGG pathway enrichment
analysis for the 3,401 genes revealed
that these genes are closely associatedwith various melanoma-related pathways, such as adherens
junction (p = 6.053 109), Wnt signaling (p = 1.673 107), path-
ways in cancer (p = 8.65 3 107), and melanogenesis pathways
(p = 4.843 104) (Figure 3E). As exemplified in Figure 3F, RAC3,
IGF1R, and TIMP2 genes show decreased 5-hmC and
increased 5-mC in gene bodies in melanomas compared with
nevi, and the 5-hmC changes are further verified by conventional
hMeDIP-qPCR assays (Figure 3G). Similarly, we also identified
517 peaks at which 5-hmC is dramatically higher (>5-fold) and
5-mC is significantly lower (>2-fold) in 926 gene promoters in
nevi compared to melanomas (Figure S3C). Gene ontology
(GO) term and KEGG pathway analyses for the 926 genes
also show that they are involved in the regulation of cell morpho-
genesis (p = 1.183 104), cytoskeleton organization (p = 0.001),
Ras protein signal transduction (p = 0.00358), posttranscrip-
tional regulation of gene expression (p = 0.0036) (Figure S3C),
and Wnt signaling pathway (p = 0.009). The 5-mC and 5-hmC
densities at representative gene promoters are shown in
Figure S3D.
Thus, this study establishes the genome-wide map of methyl-
ome and hydroxylmethylome in nevus and melanoma and
reveals the progressive loss of 5-hmC landscape in the
epigenome from begin nevus to malignant melanoma. Thus,
the demolished 5-hmC landscape is an epigenetic hallmark for
melanoma.
Downregulation of IDH2 and TET Family Members
in Melanomas
We next sought to determine the imminent cellular factors that
are directly responsible for loss of 5-hmC in melanomas. Though
the TET family of 5-mC DNA hydroxylases are directly respon-
sible for the generation of 5-hmC (Figure 4A), the catalytic reac-
tion requires cofactor a-KG (Ito et al., 2010; Tahiliani et al., 2009),
which is mainly controlled by IDHs (Xu et al., 2011a). Therefore,
we hypothesized that IDH and/or TET family enzymes play a
critical role in the establishment and maintenance of the
5-hmC landscape in the epigenome of melanocytes and their
neoplasms and downregulation of these key enzymes may be
responsible for the loss of 5-hmC in melanomas. To test this
hypothesis, we first examined the expression levels of TET and
IDH family genes in both nevi and melanomas by RT-qPCR.
Whereas IDH1 has a similar expression level between nevi and
melanomas, we found that IDH2 is significantly downregulated
in melanomas (Figure 4B). Strikingly, expression of all three
TET genes was significantly lower in melanomas than in nevi,
with the most dramatic decrease in the TET2 (Figure 4B). As
positive controls, decreased expression of tumor suppressor
gene PTEN and increased expression of cathepsin B (CTSB)
gene was observed in melanomas compared to nevi, whereas
the expression of housekeeping gene GAPDH was unchanged
(Haqq et al., 2005; Riker et al., 2008; Talantov et al., 2005).
Thus, the dramatically decreased expression of IDH2, TET1,
TET2, and TET3 is specific and may reflect the downregulated
nature of these genes in melanomas. Furthermore, the de-
creased expression of TET2 in melanomas was confirmed via
melanoma cDNA arrays (Figure 4C), and the significantly
decreased expression of IDH2 at the mRNA level was corrobo-
rated at the protein level by IHC staining (Figure 4D). These
data suggest that the diminished expression of IDH2 and/or
TET family genes in melanomas may represent one of the
molecular mechanisms underlying global loss of 5-hmC.
Overexpression of IDH2 in a Zebrafish Melanoma
Model Increases 5-hmC Levels and Prolongs
Tumor-Free Survival
To test the hypothesis that overexpression of IDH2 may result
in increased 5-hmC levels in melanoma and suppress tumor
growth, we employed a recently developed transgenic (Tg) ze-
brafish model for melanoma, in which BRAFV600E is expressed
under the control of the mitfa gene melanocyte-specific
promoter on a p53 mutant background (p53/) (Ceol et al.,
2011). Whereas the 5-hmC level was high in normal zebrafish
melanocytes shown by costaining with melanocyte-specific
mitfa (Figure 4E), 5-hmC was barely detectable in melanomas
of EGFP control animals (Figure 4F, top). IDH2 overexpression
greatly increases the 5-hmC level in melanomas compared to
those in EGFP control animals (Figure 4F, bottom), whereas
overexpression of catalytically inactive IDH2 R172K mutant
has not shown any significant effects on the 5-hmC level (data
not shown). Strikingly, tumor incidence curve analysis revealed
that IDH2 wild-type (WT)-overexpressing group, but not IDH2
R172K-overexpressing group, showed significantly increased
tumor-free survival compared to the EGFP control group (p =
7.8 3 109 by log-rank test) (Figures 4G and S4). Collectively,Cthese data suggest that the isocitrate dehydrogenase activity
of IDH2 plays an important role in maintaining proper levels of
5-hmC in melanocytes and may function as a putative tumor
suppressor for melanoma progression.
Re-Establishing the5-hmCLandscape in theEpigenome
of Human Melanoma Cells by Reintroducing TET2
We next asked whether reintroducing TET2, the most dramati-
cally decreased TET family gene in human melanomas, can
rescue the demolished 5-hmC landscape in melanoma cells.
To exclude the 5-mC hydroxylase-independent function of
TET2, we generated pure monoclonal A2058 stable cell lines
overexpressing Flag-tagged full-length WT TET2 or the iron-
binding site (H1382RD1384) disrupted catalytically inactive mutant
(TET2 M) (Figure 5A), as well as the vector only control (Mock).
The overexpression of full-length TET2 and TET2 M was verified
by western blot and RT-qPCR assays (Figures 5B and S5A).
We confirmed the global increase of 5-hmC levels in TET2-
overexpressing cells, but not TET2-M-overexpressing cells,
compared to Mock cells by dot blot and IF assays (Figures 5C
and 5D).
We next generated the genome-wide maps of 5-mC and
5-hmC in Mock, TET2-, and TET2-M-overexpressing melanoma
cells by MeDIP-seq and hMeDIP-seq, as described above (Fig-
ure S3A). Though only marginal changes in 5-mC levels among
Mock, TET2-, and TET2-M-overexpressing melanoma cells
were observed (Figures S3A and S5B), TET2-overexpressing
melanoma cells showed re-establishment of the 5-hmC land-
scape in their epigenome (Figure 5E). No significant 5-hmC level
differences were found between Mock and TET2 M cells. As
exemplified by CCND1 and MC1R genes (Figure 5F), deep
sequencing data were confirmed by conventional hMeDIP-
qPCR assays (Figure 5G).
Further bioinformatic analyses identified 15,835 peaks in
TET2-overexpressing cells whose 5-hmC densities are dramati-
cally higher (>5-fold) than in TET2 M cells. Eighty percent
(12,752/15,835) of these peaks overlap with a significant portion
(30%, 12,752/41,886) of 5-hmC peaks whose 5-hmC levels are
dramatically lower (>5-fold) inmelanomas than in nevi (Figure 5H,
left), suggesting that the 5-hmC landscape in those genomic
regions can be re-established by reintroducing TET2 in human
melanoma cells. These overlapping 5-hmC peaks were further
analyzed according to their locations (promoter or gene body)
at associated genes. We identified 2,664 Refseq genes whose
promoters have consistently higher 5-hmC densities in nevi
and TET2-overexpressing cells compared to melanomas and
TET2 M cells, respectively (Figure 5H, upper-middle). GO term
analysis reveals that these 2,664 genes are mainly associated
with intracellular signaling cascade, regulation of gene tran-
scription, cell proliferation, and morphogenesis (Figure 5H,
upper-right). Similarly, we identified 7,942 Refseq genes whose
gene bodies have consistently higher 5-hmC densities in nevi
and TET2-overexpressing cells compared to melanomas and
TET2 M cells, respectively (Figure 5H, lower-middle). Impor-
tantly, KEGG pathway analysis shows an impressive functional
association of these genes with various cancer-related path-
ways, such as focal adhesion (p = 1.9 3 1012), pathways in
cancer (p = 4.32 3 1011), adherens junction (p = 7.943 1010),ell 150, 1135–1146, September 14, 2012 ª2012 Elsevier Inc. 1139
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and melanoma (p = 5.39 3 105) as well as ErbB (p = 3.86 3
107) andMAPK (p = 2.293 106) signaling pathways (Figure 5H,
lower-right).
In summary, these biochemical and genome-wide analyses
suggest that reintroducing WT TET2, but not the TET2 catalyti-
cally inactive mutant, can significantly increase the global 5-
hmC level and re-establish, at least in part, the 5-hmC landscape
in the epigenome of human melanoma cells, which may subse-
quently affect several biological processes, such as cancer
progression.
Tumor Invasion and Growth Are Suppressed
by TET2-Mediated Re-Establishment
of the 5-hmC Landscape in Melanoma Cells
To determine the biological consequence of TET2-mediated re-
establishment of the 5-hmC landscape in melanoma cells, we
first compared the invasive ability of A2058 cells overexpressing
TET2 and TET2 M by in vitro Matrigel assay. Though these two
cell lines have similar in vitro proliferation rates (Figure 6A),
TET2-overexpressing cells show a significantly lower invasion
rate than TET2 M cells (Figure 6B). Next, we investigated the
putative tumor suppressor role of 5-hmC and TET2 using in vivo
xenograft assays. TET2- and TET2-M- overexpressing mela-
noma cells were injected into NSG mice, and tumor growth
was monitored. TET2-overexpressing melanoma cells gave
rise to significantly smaller tumors compared to TET2 M mela-
noma cells (Figures 6C and 6D). NSG mice injected with Mock
melanoma cells showed no significant differences in tumor
growth compared to TET2-M-overexpressing melanoma cells
(data not shown). Importantly, 5-hmC IHC staining of the xeno-
grafted tumor sections showed that smaller tumors derived
from TET2-overexpressing cells retained relatively high levels
of 5-hmC (Figure 6E, right). Thus, these data highlight a potential
tumor suppressor role of increased 5-hmC levels meditated by
the enzymatic activity of TET2 in melanoma.
DISCUSSION
Here, we report that loss of 5-hmC is a distinctive epigenetic
event of neoplastic progression in melanoma that correlates
with clinical relapse-free survival and melanoma staging param-
eters. Thus, 5-hmC holds promise as a putative molecular
biomarker with predictive and prognostic value. The present
study also illustrates the genome-wide 5-hmC landscape of
benign nevi and melanomas and reveals the strikingly demol-
ished 5-hmC levels and distribution along the epigenome of
melanomas in comparison with benign nevi. Furthermore,
loss of 5-hmC in melanoma is caused, at least in part, by the
decreased expression of key enzymes, IDH2 and TET family
proteins, controlling 5-hmC production. In relevant animal
models, an increase in 5-hmC levels via either IDH2 or TET2(E) Peaks at which 5-hmC is significantly reduced (>5-fold) and 5-mC is significant
and the KEGG pathway analysis results for the associated genes (right).
(F and G) MeDIP-seq and hMeDIP-seq results of RAC3, IGF1R, and TIMP2 genes
noted by red lines in (F). Data are shown as mean ± SD (n = 3) in (G).
See also Figure S3 and Table S7.
Coverexpression is shown to suppress tumor invasion and growth
and improve tumor-free survival. Taken together, the present
study provides multiple layers of evidence to support that
genome-wide loss of 5-hmC is a new epigenetic hallmark of
melanoma, with diagnostic and prognostic advantages over
global DNA hypomethylation, a recognized epigenetic mark of
cancer. Of clinical and therapeutic significance, the present
study also opens a new avenue for cancer prevention by target-
ing the cellular and biochemical pathways that can re-establish
5-hmC levels and landscape in melanoma.
The IHC staining approach to detect 5-hmC may have prac-
tical applications clinically. We and others have observed similar
loss of 5-hmC in other solid tumors such as breast, ovarian, and
colon carcinoma (data not shown) using the same methods
(Haffner et al., 2011; Yang et al., 2012). The anti-5-hmC
antibody-based IHC strategy could lead to the development
of a new, simple, sensitive, and practical adjuvant diagnostic
assay. Future studies focusing on borderline lesions and with
sufficient clinical outcome annotation are now indicated to
evaluate the utility of loss of 5-hmC as a diagnostic and
prognostic tool.
The high level of 5-hmC in differentiated and benign nevome-
lanocytes raises an intriguing question as to the nature of the
biological role of 5-hmC in melanocyte differentiation, self-
renewal, and malignant transformation. Studies of embryonic
stem (ES) cells indicate that 5-hmC may be involved in the
regulation of cell differentiation and lineage commitment (Ito
et al., 2010; Xu et al., 2011b). Until now, skin-tissue-specific
5-hmC distribution and genome-wide mapping of 5-hmC in
cancer have not been well studied. Our findings of a high level
of 5-hmC in mature melanocytes and benign nevi, as well as
a significantly lower level of 5-hmC associated with melanoma,
provide new insights supporting a role of 5-hmC in pathways
that are fundamental to cellular differentiation and dedifferen-
tiation. We postulate that the well-controlled dynamic level of
5-hmC during transition from ES cell to melanocyte progenitor
to terminally differentiated melanocyte is a epigenetic signature
of melanocyte differentiation, the perturbation of which may
lead to the induction of oncogenic pathways underlying mela-
noma progression.
There are several ways to influence 5-hmC levels in cells (Fig-
ure 4A). Presumably, dysfunction of TET and/or IDH enzymes,
two key factors involved in 5-hmC generation, would greatly
reduce 5-hmC generation. Ten percent of melanomas (4/39)
harbor an IDH1 or IDH2mutation (Shibata et al., 2011), whereas
no TET mutations have been reported in melanoma. The low
penetration of IDH and TET mutations in melanoma constitutes
robust evidence that other cancer pathways inactivating these
5-hmC-generating enzymes must play a major role in down-
regulation of 5-hmC. Herein, we demonstrate the significant
decrease in TET1, TET2, TET3, and IDH2 gene expression inly increased (>2-fold) in gene bodies in melanomas (Mel) compared to nevi (left)
(F) and hMeDIP-qPCR verifications (G). The primer-targeted regions in (G) are
ell 150, 1135–1146, September 14, 2012 ª2012 Elsevier Inc. 1141
1.0
1.5
2.0 Nevus Melanoma
***
**
***** *
e 
ex
pr
es
si
on
sA
α-Ketoglutarate
Isocitrate
CO2
Succinate
IDH1, 2
B
HP
RT
GA
PD
H
ID
H1
ID
H2
TE
T1
TE
T2
TE
T3
PT
EN
CT
SB
0.0
0.5
R
el
at
iv
e
5-mC 5-hmC
TET1, 2, 3 CO2
Fe2+
D
Nevus Melanoma
2.0
2.5 ***
***
re
ss
io
nC
No
rm
al
Me
lan
om
a I
II
Me
lan
om
a I
V
0.0
0.5
1.0
1.5 TET2
R
el
at
iv
e 
ex
pr
E
5-hmCmitfa
P<0.0001
G
40
60
80
100
fr
ee
 s
ur
vi
va
l (
%
)
IDH2 (n=77)
Merge DAPI
F 5-mC (400x)5-hmC (400x)H&E (400x)
5              10             15             20             25 
Age (weeks)
0
20
Tu
m
or
 f
EGFP (n=125)
EG
FP
H
2
ID
Figure 4. Increased 5-hmC Level by IDH2 Overexpression in a Zebrafish Melanoma Model Prolongs Tumor-Free Survival
(A) Schematic diagram of 5-hmC generation by the TET family of 5-mC DNA hydroxylases with cofactors a-ketoglutarate and Fe2+.
(B) Relative expression of genes in nevus andmelanoma by RT-qPCR. Each gene expression level was normalized to HPRT housekeeping gene. Data are shown
as the mean of three individual patients ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 by Student’s t test comparing nevus to melanoma.
(C) Relative TET2 expression in human melanoma cDNA arrays, including normal skin (n = 3), stage III melanomas (n = 21), and stage IV melanomas (n = 19) by
RT-qPCR. Data are shown as mean ± SEM. ***p < 0.001 compared the normal skin by Student’s t test.
(D) Representative IDH2 IHC staining images in nevi (n = 4) and melanomas (n = 8) at high power (4003).
(E) IF staining of 5-hmC and mitfa in normal zebrafish melanocytes. Green, mitfa; red, 5-hmC; blue, DAPI counterstain of DNA.
(F) Tumors were smaller and less invasive and had higher 5-hmC levels in miniCoopR-IDH2 zebrafish than miniCoopR-EGFP control zebrafish. Histology of the
melanomas from miniCoopR-EGFP control zebrafish and miniCoopR-IDH2 zebrafish are shown in the left panels. The hematoxylin and eosin staining of tumor
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Figure 5. TET2 Overexpression Re-Estab-
lishes the 5-hmC Landscape in the Epige-
nome of Human Melanoma Cells
(A) Schematic diagram of TET2 WT and TET2
catalytically inactive mutant (TET2 M) proteins.
(B) The expression of Flag-tagged TET2 and
Flag-tagged TET2 M proteins by western blot.
Red arrow denotes the full-length TET2 and
TET2 M bands, and red star denotes nonspecific
bands. ACTB was used as a loading control.
(C) Global 5-hmC levels in MOCK, A2058 TET2,
and A2058 TET2 M stable cell lines by dot blot
assay. The methylene blue staining was used as
total genomic DNA loading control.
(D) IF analysis of A2058 TET2 and A2058 TET2 M
stable cell lines. The Flag antibody was used to
detect Flag-tagged TET2 and Flag-tagged TET2
M. Blue, DAPI counterstain of DNA; green, Flag;
red, 5-hmC.
(E) Normalized 5-hmC tag density distribution
across the gene body. Each gene body was
normalized to 0%–100%. Normalized tag density
is plotted from 20% of upstream of TSSs to 20%
downstream of TTSs.
(F and G) MeDIP-seq and hMeDIP-seq results of
CCND1 and MC1R genes (F) and hMeDIP-qPCR
verifications (G). The primer-targeted regions in (G)
are noted by red lines in (F). Data are shown as
mean ± SD (n = 3) in (G).
(H) Venn diagrams showing the overlap between
5-hmC peaks, which are dramatically higher (>5-
fold) in nevi than in melanomas (pink), and 5-hmC
peaks, which are dramatically higher (>5-fold) in
TET2 overexpression cells compared to TET2 M
overexpression cells (blue) (left), and the associ-
ated genes according the peak location either
at gene promoter (middle-upper panel) or in gene
body (middle-lower panel). The GO term and
KEGG pathway analyses results are shown in the
right panels.
See also Figures S3 and S5 and Table S7.melanomas compared to benign nevi, which suggests that
insufficient enzymes required for the conversion of 5-mC to
5-hmC may account for one of the molecular mechanisms
underlying global loss of 5-hmC in melanomas.
In support of this hypothesis, we show that increasing 5-hmC
levels and partially re-establishing the 5-hmC landscape insections shows an infiltrative pattern of tumor in control miniCoopR-EGFP zebrafish at the body and tail junct
borders in IDH2-overexpressing zebrafish.
(G) Significant prolongation of tumor-free survival in miniCoopR-IDH2 zebrafish (n = 77) compared with min
See also Figure S4 and Table S8.
Cell 150, 1135–1146, Sepmelanoma cells by restoring expression
of active TET2 enzyme, but not the
catalytically inactive TET2 mutant, sig-
nificantly suppresses tumor growth in a
murine human melanoma xenograft
model. Importantly, this study excludes
the possibility that the tumor-suppressive
effect is due to the overexpression ofTET2 itself. Rather, such an effect is due to elevated levels
of 5-hmC on the genes that are important for key cellular
processes. Moreover, we demonstrated that a forced increase
in 5-hmC in an established zebrafish melanoma model via over-
expression of IDH2WT, but not IDH2R172Kmutant, significantly
suppressed tumor growth and prolonged tumor-free survival.ion, whereas the tumor shows much less infiltrative
iCoopR-EGFP control zebrafish (n = 125).
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Figure 6. Overexpression of TET2 in Human
Melanoma Cells Suppresses Tumor Growth
in NSG Xenograft Mice
(A) The proliferation curves of A2058 TET2 and
A2058 TET2 M stable cell lines. Data are shown as
mean ± SD (n = 4).
(B) A2058 TET2 melanoma cells show less in vitro
invasion than A2058 TET2 M melanoma cells by
Matrigel tumor invasion assay. Data are shown as
mean ± SD (n = 3). **p < 0.01 by Student’s t test.
(C) Tumor growth curves of A2058 TET2 and
A2058 TET2 M cells xenografted to NSG mice.
Data are shown as mean ± SEM (n = 10). *p < 0.05,
**p < 0.01 by Student’s t test.
(D) Representative images of tumor-bearing NSG
mice xenografted with A2058 TET2 M (left) or
A2058 TET2 cells (right) at 4 weeks post-
inoculation.
(E) H&E and 5-hmC IHC staining of TET2 M (top)
and TET2 (bottom) xenografts. The regions shown
in left panels are noted by red dash circles in (D).These data suggest that IDH2, but not IDH1, is specifically down-
regulated in melanomas and that the WT IDH2 acts as a putative
tumor suppressor in the zebrafish melanoma model, although
the IDH family of enzymes has been considered candidate
oncogenes in various tumors (Ward et al., 2010; Wrzeszczynski
et al., 2011). Nonetheless, though the nature of the putative
tumor suppressor function of IDH2 in melanoma and other tumor
types warrants future investigations, a dramatic increase in the
global 5-hmC level is the most pronounced epigenetic altera-
tion observed in both the TET2- and IDH2-overexpressing
melanoma animal models. Thus, these data demonstrate that
high levels of 5-hmC and the appropriate 5-hmC landscape in
the epigenome of melanocytes and nevus cells, both potential
melanoma progenitors, play a role in preserving the integrity of
these indolent cells and in preventing melanoma initiation and
progression. Our study supports the novel concept that an
elevated level of 5-hmC can serve as a distinctive epigenetic
molecular beacon for the reversal of an aggressive melanoma
phenotype. It further indicates that particular TET and IDH
family enzymes have putative tumor suppressor functions in
melanoma progression, and spontaneously targeted down-
regulation or inactivation of multiple key enzymes in the 5-
hmC-generating pathway is one of the epigenetic mechanisms
underlying melanoma development.
The present study also attempts to address the molecular
mechanisms directly linking the gene-specific 5-hmC loss to
melanoma formation. Genome-wide mapping and comparative
analyses of 5-mC and 5-hmC landscape in benign nevi, primary
melanomas, MOCK, TET2-, and TET2-M-overexpressing mela-
noma cells indicated that a program of genes involving various
cancer pathways display significant reduction of 5-hmC in com-
parisons between benign nevi and melanoma, which can be
reversed by overexpression of active TET2, but not inactive1144 Cell 150, 1135–1146, September 14, 2012 ª2012 Elsevier Inc.TET2 M. However, we did not find simple
correlations between significant loss of
5-hmC and expression of associatedgenes because a reduced 5-hmC level is associated with both
up- and downregulated genes in melanomas compared with
nevi. This is not surprising because we and others have shown
complex roles of 5-hmC in gene transcription regulation in
mouse ES cells (Ficz et al., 2011; Xu et al., 2011b). Thus, under-
standing the intricate relationship between the regulation of
5-hmC and associated gene transcription remains a challenge
in 5-hmC biology (Cimmino et al., 2011; Wu and Zhang, 2011).
Of note, we identified a subset of genes showing significant
5-hmC level decreases and simultaneous 5-mC level increases
in melanomas compared to nevi. The strong association of
this subset of genes with various cancer pathways suggests
that gene-specific 5-hmC loss may partially contribute to the
abnormal DNA methylation pattern in the epigenome of mela-
noma that has been linked to the progression of various cancers.
However, there are a portion of genes showing significant
reduction in 5-hmC levels but no obvious 5-mC level changes
in melanomas compared to nevi, suggesting that other indepen-
dent molecular mechanisms, such as 5-hmC-mediated regula-
tion of cell division/replication, cell differentiation/senescence,
and/or genome/epigenome instability, may also be involved in
linking the loss of 5-hmC to melanoma progression. Future
studies aimed at identifying these potential 5-hmC-related
mechanisms should enhance insights into 5-hmC function in
melanoma formation and progression.
Finally, with melanoma as a paradigm of aggressive cancer,
our study provides important insight for future functional
studies of 5-hmC in cancer biology. Increasing 5-hmC levels
via overexpressing TET2 reversed the genome-wide 5-hmC
distribution from the global 5-hmC loss pattern in melanoma
toward a benign nevus-like pattern. More importantly, the
phenotype of melanoma was rescued by increasing 5-hmC
levels via overexpressing either TET2 or IDH2 in animal
models. Thus, loss of 5-hmC in melanoma progression is a
fundamental epigenetic event that provides proof of principle
that key factors in the 5-hmC-generating pathway can be
therapeutically targeted to restore 5-hmC in human melanoma,
thus revealing new strategies for the design of melanoma
treatment.
EXPERIMENTAL PROCEDURES
Immunohistochemical Staining
Immunohistochemical (IHC) studies employed 5 mmsections of formalin-fixed,
paraffin-embedded tissue. Slides were deparaffinized and rehydrated and,
after antigen retrieval, were placed in 2N HCl for 30 min, rinsed in distilled
water, and placed in 100 mM Tris-HCl (pH 8.5) for 10 min. All were stained
on the Dako Autostainer (Dako Corporation, Carpinteria, CA) using the
EnVision (Dako) staining reagents. Sections were incubated for 60 min with
either rabbit anti-5-hmC at 1:10,000 (Active motif) or mouse anti-5-mC at
1:500 (Eurogentec) and were then incubated with the EnVision+ Dual Link
(Dako) detection reagent for 30 min. Sections were washed and treated with
a solution of diaminobenzidine and hydrogen peroxide (Dako) for 10 min,
and after rinsing, a toning solution (DAB Enhancer, Dako) was used for 2 min
to enrich the final color.
Glucosylation of Genomic 5-hmC
Genomic DNA (700ng) purified from benign nevi or melanomas was incubated
with 1 ml of T4 phage b-glucosyltransferase (NEB) and 1 ml of UDP-glucose
[6-3H] (ARC) in 1 3 NEB buffer 4 at 37C overnight, followed by protease
K digestion. DNA was purified, and radioactivity was measured by Beckman
Coulter scintillation counter LS6500.
MeDIP-Seq and hMeDIP-Seq
Genomic DNA of human melanomas, nevi, and human melanoma cell lines
was purified and sonicated. Illumina barcode adapters were ligated before
hMeDIP. Adaptor-ligated DNA (5 mg) was denatured and incubated with 3 ml
of 5-hmC antibody (Active Motif) or 10 mg of 5-mC antibody (Eurogentec) at
4C overnight. Antibody-DNA complexes were captured by protein A/G
beads. The immunoprecipitated DNA was purified and sequenced followed
by standard Illumina protocols (Xu et al., 2011b). Read sequences were
mapped to the human genome (hg19) using ELAND v2 in the CASAVA
(Illumina, v1.6) package. Significantly enriched regions were determined by
model-based analysis of ChIP-Seq (MACS) package (Zhang et al., 2008).
GO term and KEGG pathway analyses were performed by the database for
annotation, visualization, and integrated discovery (DAVID) programs (Huang
et al., 2009).
NSG Mice Melanoma Xenograft Assay
NOD/SCID interleukin-2 receptor (IL-2R) g-chain null (NSG) mice were pur-
chased from The Jackson Laboratory (Bar Harbor, ME) and maintained under
defined conditions in accordance with institutional guidelines. Experiments
were performed according to approved experimental protocols. For tumorige-
nicity studies, MOCK, WT TET2, or TET2 M A2058 melanoma cells were
injected subcutaneously into the flanks of NSGmice (13 106/injection). Tumor
growth was assayed as a time course (Schatton et al., 2008) for the duration
of the experiment or until excessive tumor burden or disease state required
protocol-stipulated euthanasia.
IDH2 Overexpression in a Zebrafish Melanoma Model
The miniCoopR assay was performed as previously described (Ceol et al.,
2011). Transgenes were expressed in zebrafish melanocytes in the back-
ground of a stably integrated BRAFV600E transgene and a p53 loss-of-function
mutation. The background also contained a mitfa loss-of-function mutation,
which blocked melanocyte development. Transgenes were coupled, via
the miniCoopR vector, to a rescuing mitfa gene, ensuring that rescued
melanocytes also expressed the transgene being tested. IDH2 was cloned
into the miniCoopR vector, and the resulting miniCoopR-IDH2 construct was
injected into single-cell zebrafish embryos. Transgenic animals were selectedCand melanoma onset measured weekly as compared to miniCoopR-EGFP
control animals. Animals with melanomas were isolated, and tumors were
allowed to progress for 2weeks prior to being sacrificed. Tumorswere formalin
fixed, embedded, and sectioned transversely to assess invasion.
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